Isomorphic Labs has raised $5 billion to design new medicines with AI. In our view, that determine measures investor perception, not a drug that sufferers can already use.
The London company set out the $5 billion Series C, an advanced private fundraising round, in a statement dated 17 November. It known as the spherical oversubscribed. Two funding companies, Greenoaks and Sequoia Capital, co-led it. Andreessen Horowitz and a number of other different new backers joined, and Alphabet, the mother or father of Google, made what the corporate known as a continued important funding. Each current investor additionally took half, together with Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, a government-backed UK fund.
The same company raised $2.1 billion in a Series B round announced on 12 May. Taken collectively, the 2 cheques come to $7.1 billion in simply over six months.
What the cash is shopping for
The brand new funds will go into the agency’s drug design engine, known as IsoDDE, and right into a set of candidate medicines designed with AI. That engine is a set of simulation fashions used to look by means of chemical choices and suggest molecules. The corporate says this work is already “yielding positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry.” Preclinical outcomes are findings from assessments finished earlier than a drug is given to folks, normally in cells or animals.
Sir Demis Hassabis, the founder and chief govt, was clear about the place the programmes stand. “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” he mentioned in the identical assertion. In direction of scientific trials means these programmes haven’t but reached the purpose the place they’re examined in folks.
The firm already lists research collaborations with three large drugmakers. These companions are Novartis, Eli Lilly and Johnson & Johnson. The Novartis work, first agreed in 2024 and later expanded, is aimed toward small-molecule medicine in opposition to troublesome targets. The opposite two partnerships are additionally analysis pacts, not authorised medicines.
A big cheque nonetheless buys candidates, not a capsule
The $5 billion determine is actual and checkable. Additionally it is, by one specialist depend, unusually massive. A trade publication that tracks 26 drug companies said these two rounds were the biggest venture cheques it had recorded in the sector this year, and that the $5 billion round was the largest financing in its records since 2022.
Our studying is less complicated than discuss of the following technology of medicines. The corporate is promoting a way and a listing of candidates. It has not mentioned that any of its candidates have entered human trials. Till that occurs, the $5 billion is a value on perception: that simulation fashions can design molecules effectively sufficient to outlive the a lot tougher check of security and profit in folks.
That’s not a dismissal of the science. Preclinical outcomes could be a real step. They’re additionally the stage at which most drug candidates later fail. A fundraising spherical of this measurement doesn’t change that filter. It solely buys extra makes an attempt.
On 5 August, the founder handed over day-to-day management of Google DeepMind, Google’s AI lab. In a joint staff note that day, he said he would lean further into this drug company. The lab’s earlier protein-folding work is a part of the scientific backdrop. We covered the next version of that system when it was released. It’s not the identical factor as a completed medication.
Why it issues
A $5 billion cheque is likely one of the clearest numbers within the AI economic system this week, and it was written for an organization that will likely be judged by scientific trials, not by app customers. That check has not began but, and readers ought to maintain the quantity and the record of candidates in separate columns.

